CME Credit Quiz

In association with Dalhousie University



This test offers the opportunity to assess your knowledge and retention of the information presented in the articles in this issue. Physicians who complete the quiz will receive a statement from Dalhousie University, Continuing Medical Education indicating their participation and their score.

Dalhousie University is fully accredited by the Committee on Accreditation of Canadian Medical Schools and, by reciprocity, the Accreditation Council for Continuing Medical Education of the United States to offer continuing medical education to physicians.

Where applicable, physicians may report their participation in this CME activity to the appropriate professional and health organizations.

Each quiz may be submitted only once for consideration and must be submitted within six months after the date of issue.

Correct answers will be published in the journal six months after the quiz appears.

SELECT THE BEST ANSWER(S) FOR EACH OF THE FOLLOWING

- 1. How many of the following symptoms are required for the diagnosis "premenstrual dysphoric disorder" (PMDD): Sadness, tenseness, marked lability, irritability.
- a) 1

c) 3

b) 2

- d) 4
- 2. The simple approach for women with PMDD is lifestyle and dietary modification of which of the following?
- a) Carbohydrate consumption
- b) Salt consumption
- c) Caffeine consumption
- d) Encouragement of daily exercise
- e) All of the above
- 3. Biological risk factors for perimenopausal depression include which of the following?
- a) History of PMDD
- b) Postpartum depression
- c) Surgical menopause
- d) A and B
- e) All of the above
- 4. Estrogen replacement therapy is recommended for which of the following perimenopausal symptoms?
- a) Hot flashes
- d) Insomnia
- b) Vaginal dryness
- e) All of the above
- c) Decreased libido

- 5. Women who have had depression in a previous pregnancy are at what risk of a recurrent episode?
- a) 10%
- c) 30%
- e) 50%
- b) 25%
- d) 43%
- 6. "Maternity Blues" usually do not last more than:
- a) Five days c) 14 days
- b) 10 days d) 25 days

(Reproductive Mental Health, page 59)

- 7. In the prone position, excess internal rotation of the hip is:
- a) Femoral retroversionb) Femoral anteversion
- c) Tibial tortion
- 8. Club foot is a deformity in which category?
- a) Forefoot adduction
- b) Forefoot neutral to abduction
- 9. In which of the following is the incidence of the same deformity among first-degree relatives 20- to 30-times higher than normal incidence?
- a) Metatarsus adductus
- b) Club foot
- c) Postural calcaneovalgus
- d) Congenital vertical talus

10. A true club foot is a flexible deformity that can be manipulated to full correction.

- True
- b) False

- 11. Congenital vertical talus may be isolated, but often is associated with:
- a) Arthrogryposis
- d) A and C
- b) Down's syndrome
- e) All of the above
- c) Spina bifida

(Foot Deformities in the Infant, page 81)

Please indicate your answers on the attached quiz reply form and mail to: **Dalhousie University** Continuing Medical Education 5849 University Avenue Halifax, Nova Scotia B3H 4H7

Made possible through an educational grant from Merck Frosst Canada LTD.



60 mg & 100 mg Film-coated tablets Gastrointextinal Calcium Antagonist

CLERCAL PHARMACTED BY

BICETE: (sincertum bronds) is a calcium entagonist which inhibits the calcium influx by blocking the vollage-dependent calcium channel at the emocth muscle cell level. It possesses a high dagree of selectivity for the intestinal smooth rounds. Many studies showed that pineventum bronide induces a relaxation of the questointestinal and the billing treats and meinly of the parameters in the tries will be seen in the property of the color, as inhibition of the motor colorie, implying the extent of the drug in inflictic bowel syndrome.

BENEZATIONS AND CLUBEM, USE

- BIGETEL* (pinswerium bromkin) is indicated: for the treatment and railef of symptoms associated irritable borni syndrome (BS); sixtomiral pain, bosed disturbance and intestinal discomfort.
- for the treatment of symptoms related to functional disorders of the billiary tract.

CONTRANGUEATURES
DICETEL (pineverlum bromids) is contraindicated in patients with known hypersensitivity to plansverien bromide or any of the accipients. We either contraladications have been Hernified at this time.

Contact of DICETEL* (pinevertum bromide) with the construged mucous may be influting. Therefore, it is strongly recommended that the tablet be taken with a glass of water claring meeting. If more than three tablets are prescribed par day, the additional but left should be taken concurrently with a glass of water and a exact.

DICETEL? (planestum broadds) should not be administrated for the relief of metility dynamiction due to underlying organic disease.

libs is pregners; Reproductive studies performed in les in commence, Reproductive studies performed in minusis have not revealed the presence of tentiopenic offects. However, the safety of DICETEL' during programsy has not been established. Commencetty, in the programs patient, this drug should only be adminishmed if, in the judgment of the physician, its use is examinate the welliam of the pullent. There have been no controlled the first patients. There have been no controlled the first patients.

studies in numbing women, therefore, the drug should be excided during lectation.

AUTORIO REACTIONS

Authorized researches where reported and dated as mild and moderate. They were resinly minor elgestive disorders that may be related to the disease, such as epigmatic pain motor fallness (0.8%), neuros (0.5%), costipation (0.4%). However, the second of the mouth (0.3%), diseased the mouth (0.3%).

In man, sport from distribuse under finishmen, DICETEL* (pineurium bromido) induced no underinable effects in fally designs of up to 1,200 mg. No cause of overdomps of DICETEL* have been reported to date. However, if of DESTE: have been reported to date. However, if everdenage occurs, gestric longe in moonmended and symptometic fredment initiated if deemed recessary.

eversomage occurs, gastric ferage in recommended and ayraptemetric treatment initiated if deemed necessary. Distable AND ADMINISTRATION

The reuse actual deepe is 50 mg three times a day (total delly does of 150 mg). The doesgo may be increased up to a measurum of 100 mg taken three times a sizy (measurum total delly does of 300 mg). It is recommended that the tablet be taken with a glass of water during meets or whech it to taken with a glass of water during meets or whether the tablet of thould not be swellowed when in the lying position or just before betiling. The duration of treatment depends on the disorders for which DISETEL? Is given.

MOLABLITY OHGETTEL* (pinnverture bromide) is excitable as: 50 mg Rhm-control Tableto: Each orange-coloured, chauter-shaped, film-cooked tablet with a slightly convex surface contains 50 mg st phaserium bronida an active lagredient. The biblet is disbosed with "S" on one side and "50" on the revene side. Available in bilister packs, in boses of 100 tablets.

100 mg. Filer-context Tableto: Each orange-coloured, circular-shaped, film conted tablet with a slightly convex surface contains 100 mg of phresentum bromble as eather ingredient. The tablet is disbussed with "8" on one side and "100" on the reverse side. Assibable in blister packs, in bosse of 100 tableto.

- Film-control Tublete: In addition to pleaverium brombio, DUCEPEL* contains the following exciplents:

 In the core: microcrystelline solutions, medified core steret, modified lecture, hydrophobic anhydrous allice, tute and magnetium statemics.
- tele and magnetium stands.

 In the film costing, gestrosoluble scryic resin, microsized tele, polyocyclhylere glycol 6000, Sepisperas orange K3020 (tientum dioxide (£ 171), conset yellew luke (£ 110), hydroxy propylectulose (£ 463).

 STABLITY AND STOKAGE RECOMMENDATIONS
 The abbillty of ENEREY tim-coded bablets has been demonstrated in this dispensing box. DEEPELY should be showed in the dispension by CCC to 3050 in the

istored at room temperature (15°C to 30°C) in its والمحملة

Product monograph evallable upon request.
*Registered Trademark used under Ecoses by Solvey Pherme Inc.

Solvay Pharma bouw

80 Columbie Wey, Suite 102, Markhaun, Ontario LAR OCE

